Novasep has announced that it has been selected by Tetraphase for the commercial manufacture of the active pharmaceutical ingredient (API) eravacycline, an antibiotic being developed for the treatment of life-threatening infections, including those caused by multidrug-resistant, Gram-negative bacteria.   This manufacturing agreement with Tetraphase is the result of a successful collaboration that started in 2014 with the clinical supply of eravacycline.    Dr Michel Spagnol, chai...